Re:Thanks, HN: You helped discover a disease and save lives
by dnautics on Thursday July 17, 2014 @08:34PM
(#8051076)
the inhibitor to NGLY1 would not be able to rescue the frame-shifted variant, it might be able to rescue the other variant, under certain conditions, unless that variant knocks out the active site (I can't remember from the original manuscript if it does or doesn't, and I can't seem to find it). Sorry for the lexical confusion.
Also, on re-reading the description of NGLY1 (it's been 2 years) I realized that an acetyl-nojirimycin might be a better choice! Looks like my intuition was correct.
We'd been considering N-acetyl-dideoxy-nojirimycin (2-ADN) to inhibit a different enzyme related to NGLY1. (I can't discuss more publicly since the research is unpublished, but would be happy to discuss over email.)
Can you explain a little more about how an inhibitor for NGLY1 could rescue the frame-shifted (non-nonsense) variant?